Product Information
AP20187 is a small molecule inhibitor of the bcr-abl kinase, an enzyme that regulates cellular proliferation and apoptosis. It has been shown to be effective in treating primary sclerosing cholangitis (PSC) and chronic lymphocytic leukemia (CLL). This drug inhibits the activity of the receptor tyrosine kinase BCR-ABL, which is important in the regulation of cell division, differentiation, and apoptosis. AP20187 has been shown to inhibit the growth of xenograft tumors in vivo and block axonal growth by inhibiting tumor necrosis factor alpha (TNF-α) production. The drug also induces pro-apoptotic protein expression in vitro.
Chemical properties
Technical inquiry about: 3D-VHA51480 AP20187
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
